Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Jul 20;27(21):3437-44.
doi: 10.1200/JCO.2008.18.9068. Epub 2009 May 26.

Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients

Brandon L Pierce  1 , Rachel Ballard-Barbash, Leslie Bernstein, Richard N Baumgartner, Marian L Neuhouser, Mark H Wener, Kathy B Baumgartner, Frank D Gilliland, Bess E Sorensen, Anne McTiernan, Cornelia M Ulrich
Affiliations

Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients

Brandon L Pierce et al. J Clin Oncol. .

Abstract

PURPOSE Chronic inflammation is believed to contribute to the development and progression of breast cancer. Systemic C-reactive protein (CRP) and serum amyloid A (SAA) are measures of low-grade chronic inflammation and potential predictors of cancer survival. PATIENTS AND METHODS We evaluated the relationship between circulating markers of inflammation and breast cancer survival using data from the Health, Eating, Activity, and Lifestyle (HEAL) Study (a multiethnic prospective cohort study of women diagnosed with stage 0 to IIIA breast cancer). Circulating concentrations of CRP and SAA were measured approximately 31 months after diagnosis and tested for associations with disease-free survival (approximately 4.1 years of follow-up) and overall survival (approximately 6.9 years of follow-up) in 734 disease-free breast cancer survivors. Cox proportional hazards models were used with adjustment for potential confounding factors to generate hazard ratios (HRs) and 95% CIs. Results Elevated SAA and CRP were associated with reduced overall survival, regardless of adjustment for age, tumor stage, race, and body mass index (SAA P trend < .0001; CRP P trend = .002). The HRs for SAA and CRP tertiles suggested a threshold effect on survival, rather than a dose-response relationship (highest v lowest tertile: SAA HR = 3.15; 95% CI, 1.73 to 5.65; CRP HR = 2.27; 95% CI, 1.27 to 4.08). Associations were similar and still significant after adjusting for self-reported history of cardiovascular events and censoring cardiovascular disease deaths. Elevated CRP and SAA were also associated with reduced disease-free survival, although these associations were of borderline significance (SAA P trend = .04; CRP P trend = .07). CONCLUSION Circulating SAA and CRP may be important prognostic markers for long-term survival in breast cancer patients, independent of race, tumor stage, and body mass index.

PubMed Disclaimer

Conflict of interest statement

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Figures

Fig 1.
Fig 1.
Cohort definition and exclusions. CRP, C-reactive protein; SAA, serum amyloid A; BMI, body mass index.
See this image and copyright information in PMC

References

    1. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860–867. - PMC - PubMed
    1. Schultz DR, Arnold PI. Properties of four acute phase proteins: C-reactive protein, serum amyloid A protein, alpha 1-acid glycoprotein, and fibrinogen. Semin Arthritis Rheum. 1990;20:129–147. - PubMed
    1. Uhlar CM, Whitehead AS. Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem. 1999;265:501–523. - PubMed
    1. Manley PN, Ancsin JB, Kisilevsky R. Rapid recycling of cholesterol: The joint biologic role of C-reactive protein and serum amyloid A. Med Hypotheses. 2006;66:784–792. - PubMed
    1. McArdle PA, Mir K, Almushatat AS, et al. Systemic inflammatory response, prostate-specific antigen and survival in patients with metastatic prostate cancer. Urol Int. 2006;77:127–129. - PubMed

Publication types